WASHINGTON, Nov 30 (Reuters) - The U.S. Food and Drug Administration plans to loosen its stance on the ability of pharmaceutical companies to promote their drugs for uses not yet approved, a U.S. lawmaker said on Friday.A draft policy describes conditions under which drugmakers can distribute medical studies to doctors about their products, for uses not yet cleared by the FDA, according to Rep. Henry Waxman, the Democratic chair of the House panel on oversight and government reform, who released the FDA document.
